Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRD | O14764 | 2/20 | 0.73 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.73 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.73 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.73 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.73 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.73 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.73 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | NAMPT | P43490 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631346 | 0.91 | L3MBTL3 (0.64) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL7170182 | 0.91 | NAMPT (0.65) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL4229238 | 0.86 | GABRD (0.71) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL14742135 | 0.85 | NAMPT (0.66) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL17888421 | 0.84 | GABRD (1.00) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL5446400 | 0.83 | CHRM2 (0.65) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL894920 | 0.83 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL28393 | 0.83 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL6634031 | 0.82 | NAMPT (0.66) | SIGMAR1NAMPTCYP1A2CYP2D6 | |
| SCHEMBL6634743 | 0.82 | HSD17B10 (0.60) | GABRDGABRA1GABRB1GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1678178-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040167-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | CCR8, CCR1, CCR10 | GABRD 725/4885GABRA1 789/4885GABRB1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.